A novel in vitro toxicological approach to identify chemicals with a prostate-mediated effect on male reproduction

Journal of Biological Research (Italy)

Volumn 84, Issue 1, 2011, Pages 36-41

  Lorenzetti, S ^a   Narciso, L ^a   Marcoccia, D ^a   Altieri, I ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

In vitro alternative method; LNCaP; Prostate; Prostate specific antigen (PSA); ReProTect

Indexed keywords

EID: 85015421490     PISSN: 18268838     EISSN: None     Source Type: Journal    
DOI: 10.4081/jbr.2011.4487     Document Type: Article

References (30)

1. Schenk B., Weimer M., Bremer S., van der Burg B., Cortvrindt R., Freyberger A., Lazzari G., Pellizzer C, Piersma A., Schafer WR., Seiler A., Witters H., Schwarz M.2010.The ReProTect Feasibility Study, a novel comprehensive in vitro approach to detect reproductive toxicants. Reprod.Toxicol., 30(1): 200-218.
2. Anonymous 2005.The Fourth EC report on the statistics on the number of animals used for experimental and other scientific purposes in the Member States of the European Union. COM/2005/7 final. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=COM:2005:0007:FIN:EN:PDF.
3. Anonymous 2001.White Paper on a strategy for a Future Chemicals Policy (COM(2001)88 final). Brussels:The Commission of the European Communities. http://europa. eu.int/comm/environment/chemicals/whitepaper.htm.
4. Russel W.M.S., Burch R.L 1959. The principles of humane experimental technique, Methuen & Co. Ltd., London.
5. Hareng L, Pellizzer C, Bremer S., Schwarz M., HartungT 2005.The integrated project ReProTect a novel approach in reproductive toxicity hazard assessment. Reprod.Toxicol., 20(3): 441-452.
6. http://www.reprotect.eu
7. Lorenzetti S., LagattaV., Marcoccia Q.Aureli R.Cubadda R, Arico E., Canini I., Castiello L, Parlato S., Gabriele L, Maranghi F., Mantovani A. 2008. Functional assays, integrated with gene expression signatures, as predictive toxicological biomarkers: from toxicogenomics to phenotypic anchoring.Toxicol. Lett, 180S(S1):S123-S124.
8. Lorenzetti S., Marcoccia D., Narciso L, Mantovani A. 2010. Cell viability and PSA secretion assays in LNCaP cells: a tiered in vitro approach to screen chemicals with a prostate-mediated effect on male reproduction within the ReProTect project Reprod.Toxicol., 30(1): 25-35.
9. Woodruff TJ., Carlson A., Schwartz J.M., Giudice L.C. 2008. Proceedings of the summit on environmental challenges to reproductive health and fertility: executive summary. Fertil. Steril., 89(2Suppl.):e1-e20.
10. Bremer S., Balduzzi D., Cortvrindt R., Daston G., Eletti B., Galli A., Huhtaniemi I., Laws S., Lazzari G., Liminga U., Smitz J., Spano M., ThemmenA., TilloyA., Waalkens-Behrends 1.2005. The effects of chemicals on mammalian fertility.The report and recommendations of ECVAM Workshop 53-the first strategic workshop of the EU ReProTect Project. Altern. Lab. Anim., 33(4): 391-16.
11. Mantovani A., Maranghi F. 2005. Risk assessment of chemical potentially affecting male fertility. Contraception, 72(4): 308-313.
12. Shaughnessy P.J., Morris I.D., Huhtaniemi I., Baker RJ., Abel M.H. 2009. Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: data from mutant and genetically modified mice. Mol. Cell Endocrinol., 306(1-2): 2-8.
13. Jonsson M., Lundwall A., Malm J. 2006.The semenogelins: proteins with functions beyond reproduction? Cell. Mol. Life Sci., 63(24): 2886-2888.
14. Veveris-LoweT.L, Kruger S.J., Walsh T, Gardiner R.A., Clements J.A. 2007. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. Semin.Thromb. Hemost, 33(1): 87-99.
15. Clements JA.Willemsen N.M., Myers S.A., DongY. 2004.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev. Clin. Lab. Sci., 41 (3): 265-312.
16. Balk S.P., Ko Y.J., Bubley G.J. 2003. Biology of prostate-specific antigen. J. Clin. Oncol., 21 (2): 383-391.
17. Pampalakis G., Sotiropoulou G. 2007.Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys.Acta, 1776(1): 22-31.
18. Lundwall A., Brattsand M. 2008. Kallikrein-related peptidases. Cell Mol. Life Sci., 65(13): 2019-2038.
19. Kim J., Coetzee G.A. 2004. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem., 93(2): 233-241.
20. McPhaul M.J. 2008. Mechanisms of prostate cancer progression to androgen independence. Best Pract, Res, Clin, Endocrinol, Metab., 22(2): 373-388.
21. Finne R.Finne R., Auvinen A., Juusela H., Aro J., Maattanen L, Hakama M., Rannikko S., TammelaT.L, Stenman U. 2000. Predicting the outcome of prostate biopsy in screen-positivemen by amultilayer perceptron network. Urology, 56(3): 418-422.
22. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H, ChuT.M., Mirand E.A., Murphy G.R 1983. LNCaP model of human prostatic carcinoma. Cancer Res., 43(4): 1809-1818.
23. Fizazi K., Navone N.M. 2005 Preclinical models of prostate cancer. Bull. Cancer., 92(2): 129-141.
24. European Commission 1996. European workshop on the impact of endocrine disrupters on human health and wildlife. Report of proceedings from a workshop held in Weybridge, UK, 2-4 December 1996. Report reference, EUR 17549, European Commission, DGXII, Brussels, Belgium.
25. VinggaardA.M., Niemela J.B., Wedebye E., Jensen G.E. 2008. Screening of 397 Chemicals and Development of a Quantitative Structure-Activity Relationship Model for Androgen Receptor Antagonism. Chem. Res.Toxicol., 21(4): 813-823.
26. Li J., Gramatica P. 2010. Classification and Virtual Screening of Androgen Receptor Antagonists. J. Chem. Inf. Model., 50(5): 861-874.
27. Harvey A.L, Cree I.A. 2010. High-throughput screening of natural products for cancer therapy. Planta Med. 76(11): 1080-1086.
28. Schulte-Hermann R., Wogan G.N., Berry C, Brown N.A., Czeizel A., Giavini E., Holmes LB., Kroes R., Nau H., Neubert D., Oesch E.OttT., Pelkonen O., Robert-Gnansia E., Sullivan F.M. 2006. Analysis of reproductive toxicity and classification of glufosinate-ammonium. Regul.Toxicol. Pharmacol., 44(3 Suppl.1):S1-S76.
29. Freyberger A., Witters H., Weimer M., LofinkW, Berckmans R.Ahr H.J. 2010. Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Reprod.Toxicol., 30(1): 9-17.
30. Wetherill Y.B., Fisher N.L, Staubach A., Danielsen M., deVere White R.W, Knudsen K.E. 2005. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res., 65(1): 54-65.